Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing oral live biotherapeutic products (LBPs), or bacterial consortia, for medically vulnerable patients and people with inflammatory and immune diseases. Its pipeline includes SER-155, being evaluated for immune checkpoint-related… From the company’s description.
In fiscal 2025, Seres Therapeutics, Inc. reported revenue of $0.79M and net income of $5.70M. Operations generated $1.12M in cash. Over the twelve months to Sep 30, 2026, revenue was $2.13M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Seres Therapeutics, Inc. does
In the company’s own words
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing oral live biotherapeutic products (LBPs), or bacterial consortia, for medically vulnerable patients and people with inflammatory and immune diseases. Its pipeline includes SER-155, being evaluated for immune checkpoint-related enterocolitis and developed to prevent infections in patients undergoing allogeneic stem cell transplantation; SER-603, in preclinical development for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; and SER-147, designed to prevent infections in patients with metabolic disease. The company uses a microbiome discovery and development platform combining human data, microbial strain libraries, screening and analytics, and maintains manufacturing capabilities for LBPs. Seres led the development of VOWST, the first FDA-approved orally administered microbiome therapeutic, and sold it to Nestlé Health Science in September 2024. The company reports one headline scale metric: research and development operations span clinical studies and proprietary manufacturing capabilities. Its website is https://www.serestherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1609809
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Seres Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Seres Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Seres Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Seres Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Seres Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”